Lifevantage (NASDAQ:LFVN) Posts Earnings Results, Misses Estimates By $0.01 EPS

Lifevantage (NASDAQ:LFVNGet Free Report) issued its earnings results on Thursday. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01), FiscalAI reports. Lifevantage had a return on equity of 23.89% and a net margin of 2.94%.

Lifevantage Price Performance

NASDAQ LFVN traded down $0.16 during trading hours on Thursday, hitting $6.45. 98,308 shares of the company’s stock traded hands, compared to its average volume of 272,217. The company has a market capitalization of $81.40 million, a PE ratio of 14.33 and a beta of 0.72. Lifevantage has a 52-week low of $3.90 and a 52-week high of $14.28. The firm’s 50-day moving average is $6.42 and its 200-day moving average is $5.83.

Lifevantage Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Tuesday, September 1st. Lifevantage’s dividend payout ratio is currently 44.44%.

Institutional Investors Weigh In On Lifevantage

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its position in shares of Lifevantage by 5.4% during the 1st quarter. Jane Street Group LLC now owns 36,567 shares of the company’s stock valued at $533,000 after buying an additional 1,877 shares during the period. Cetera Investment Advisers raised its holdings in Lifevantage by 10.8% in the 2nd quarter. Cetera Investment Advisers now owns 20,098 shares of the company’s stock valued at $263,000 after buying an additional 1,954 shares during the period. Invesco Ltd. lifted its stake in Lifevantage by 13.6% during the 4th quarter. Invesco Ltd. now owns 30,085 shares of the company’s stock worth $185,000 after acquiring an additional 3,603 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Lifevantage by 870.2% during the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after acquiring an additional 4,499 shares during the period. Finally, LPL Financial LLC boosted its stake in shares of Lifevantage by 19.0% in the 4th quarter. LPL Financial LLC now owns 28,303 shares of the company’s stock valued at $174,000 after buying an additional 4,524 shares during the period. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LFVN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Lifevantage in a research report on Friday, August 21st. Lake Street Capital lowered Lifevantage from a “buy” rating to a “hold” rating and set a $5.00 price objective on the stock. in a report on Thursday, May 7th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.00.

View Our Latest Analysis on LFVN

About Lifevantage

(Get Free Report)

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.

Read More

Earnings History for Lifevantage (NASDAQ:LFVN)

Receive News & Ratings for Lifevantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifevantage and related companies with MarketBeat.com's FREE daily email newsletter.